Tirzepatide
Tirzepatide (Mounjaro, Zepbound)
Dual GIP/GLP-1 agonist. Stronger weight loss than semaglutide in trials.
Typical vial sizes
Sample reconstitution
10 mg vial · 2 mL bac water · 8.75 mg dose
- Draw volume
- 1.750 mL
- Insulin units
- 175 units
- Concentration
- 5.00 mg/mL
- Doses per vial
- 1.1
Research notes
Titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15mg.
From the blog
- Tirzepatide for MASH: What the SYNERGY-NASH Phase 2 Trial Actually Showed
Tirzepatide is best known as the dual GIP/GLP-1 receptor agonist marketed for type 2 diabetes and for chronic weight management. But one of the most-discussed datasets around the molecule concerns a different organ entirely: the liver. In 2024, the *
- VK2735: Viking's GLP-1/GIP Dual Agonist in Subcutaneous and Oral Development
VK2735 is an investigational drug candidate from Viking Therapeutics, developed as a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Viking is pursuing it in two forms — a weekly s
Further reading
Links open live searches on authoritative databases — verify dosing and safety against primary sources.
Research use only.
Information on this page is a reference log compiled from public sources and is not medical advice. Consult a licensed physician before making any decisions about your health.